 |
12 Companies | 12 Products |
|
|
12 Products | |
0 Diseases | |
115 Trials |  |
7682 News |  |
| «12...89101112131415161718...2021» |
- || Clinical, Journal: Efficacy and Safety of Inhaled Glycopyrronium Bromide in COPD: A Randomized, Parallel Group, Dose-Ranging Study (GLIMMER). (Pubmed Central) - Nov 25, 2021
The incidence of adverse events, both overall and for the most common preferred terms, was low and similar in all treatment groups, including placebo (overall, 22.3-29.3%). Based on the totality of the efficacy and safety data, the optimal GB dose is 25 µg BID.
- | Journal: Two binding epitopes modulating specificity of immunoassay for β-agonist detection: Quantitative structure-activity relationship. (Pubmed Central) - Nov 25, 2021
Tert-butyl at C-2' epitope is needed to generate class specific antibodies, and different characteristics of substituents at benzene ring epitope would adjust antibody specificity. This investigation could provide reference for future design of β-agonist haptens.
- | Preclinical, Journal: Estradiol regulation of the prelimbic cortex and the reinstatement of cocaine seeking in female rats. (Pubmed Central) - Nov 24, 2021
These effects coincide with an ERβ- and GPER1-dependent suppression of GABA-mediated inhibition of pyramidal neurons that likely increases the excitability of prefrontal cortical output pathways involved in drug seeking. Determining how estrogens influence behavior via effects in the prefrontal cortex is important for understanding both adaptive and maladaptive behaviors, including substance use, and has the potential to guide treatment.
- | Preclinical, Journal: Estrogen receptor β contributes to both hypertension and hypothalamic plasticity in a mouse model of peri-menopause. (Pubmed Central) - Nov 24, 2021
Finally, deleting PVN ERβ in intact female mice produced a phenotype characterized by sensitivity to AngII hypertension. These results provide preclinical evidence supporting a therapeutic window of opportunity for management of hypertension by ERβ agonists as women transition through menopause.
- || Clinical, Journal: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease. (Pubmed Central) - Nov 21, 2021
These results provide preclinical evidence supporting a therapeutic window of opportunity for management of hypertension by ERβ agonists as women transition through menopause. We believe this treatment combination is optimal for patients with lung cancer and COPD.
- || propranolol / Generic mfg.
Retrospective data, Review, Journal: The association between developing Parkinson's disease and β-Adrenoceptor acting agents use: A systematic review and meta-analysis. (Pubmed Central) - Nov 18, 2021
We believe this treatment combination is optimal for patients with lung cancer and COPD. Overall β-antagonists, including propranolol and metoprolol, were associated with an increased risk of PD, in contrast to β-agonists, which were associated with decreased the risk.
- | Journal: KairoSight: Open-Source Software for the Analysis of Cardiac Optical Data Collected From Multiple Species. (Pubmed Central) - Nov 17, 2021
We also demonstrate cardiac responsiveness to ryanodine (ryanodine receptor modulator) and isoproterenol (beta-adrenergic agonist) and highlight regional differences after an ablation injury. KairoSight can be employed by both basic and clinical scientists to analyze complex cardiac optical mapping datasets without requiring dedicated computer science expertise or proprietary software.
- | propranolol / Generic mfg.
Preclinical, Journal: Evaluation of Effects of Ractopamine on Cardiovascular, Respiratory, and Locomotory Physiology in Animal Model Zebrafish Larvae. (Pubmed Central) - Nov 17, 2021
To validate our results, we co-incubated a well-known β-blocker of propranolol (PROP) with RAC...Taken together, our studies provide solid in vivo evidence to support that RAC plays crucial roles on modulating cardiovascular, respiratory, and locomotory physiology in zebrafish for the first time. In addition, the versatile functions of RAC as β-agonist possibly mediated via receptor competition with PROP as β-antagonist.
- | Journal: Beta-agonist Exposure Preferentially Impacts Lung Macrophage Cyclic AMP Related Gene Expression in Asthma and Asthma COPD Overlap Syndrome. (Pubmed Central) - Nov 12, 2021
Key BALcAMP genes demonstrate significantly decreased expression in severe asthmatics in the IMSA cohort. We conclude that suppression of the BALcAMP gene module identified from SARP BAL samples is validated in the IMSA patient cohort with physiologic parallels observed in a monocytic cell line and in a severe ACOS patient sample with effects preferentially localizing to macrophages.
- || Stiolto Respimat (olodaterol/tiotropium FDC) / Boehringer Ingelheim
Clinical, Journal: COPD Maintenance Therapy with Tiotropium/Olodaterol Compared with Tiotropium: An Analysis in the Absence of Additional ICS Therapy. (Pubmed Central) - Nov 11, 2021
Tiotropium/olodaterol therapy significantly improved lung function, symptoms and health status compared with tiotropium alone. In a population free from ICS treatment, these data confirm the benefits of dual bronchodilation versus monotherapy.
- | Journal: Thyroid hormone analogues: an update. (Pubmed Central) - Nov 7, 2021
3-iodothyronamine (T1AM) is the last entry in the group of active TH metabolites. Promising results have been obtained in animal models of neurological injury induced by -amyloid or by convulsive agents, but no clinical data are available so far.
- || Fasenra (benralizumab) / AstraZeneca
Clinical, Journal, Real-world evidence: Real world effectiveness of benralizumab on respiratory function and asthma control. (Pubmed Central) - Nov 6, 2021
The notable improvement in respiratory function is a significant result in this study and it is much higher than what has emerged to date. This result, together with the OCS sparing effect and the excellent clinical control of asthma, makes benralizumab a reliable and safe therapeutic option for SEA.
- || Clinical, Journal: Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study. (Pubmed Central) - Nov 5, 2021
SABA overuse was found in 2%-4% of patients in Korea. SABA overuse was associated with an increased risk of mortality.
- || Clinical, Journal: Congenital myasthenic syndrome in Turkey: clinical and genetic features in the long-term follow-up of patients. (Pubmed Central) - Nov 4, 2021
Patients can get serious benefits and recover after the treatment. The treatment should be planned according to genetic tests and clinical findings.
- | Journal: Vitamin D and lumisterol derivatives can act on liver X receptors (LXRs). (Pubmed Central) - Nov 4, 2021
Molecular dynamics simulations for the selected compounds, including 1,25(OH)D3, 1,20(OH)D3, 25(OH)D3, 20(OH)D3, 20(OH)L3 and 20,22(OH)L3, showed different but overlapping interactions with LXRs. Identification of D3 and L3 derivatives as ligands for LXRs suggests a new mechanism of action for these compounds.
- || Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Review, Journal: Indacaterol/Glycopyrronium/Mometasone: A Review in Asthma. (Pubmed Central) - Nov 4, 2021
Indacaterol/glycopyrronium/mometasone was generally well tolerated, and the most common adverse events were respiratory in nature. In conclusion, combination therapy with indacaterol/glycopyrronium/mometasone represents a valuable option for the maintenance treatment of asthma, with the convenience of once-daily administration via a single inhaler.
- || clozapine / Generic mfg.
Clinical, Journal: Paradoxical refractory hypotension following adrenaline administration in a patient taking clozapine. (Pubmed Central) - Nov 4, 2021
This effect is likely due to uninterrupted β-agonist activity in the presence of clozapine-induced α-blockade. Clinicians need to have greater awareness of this serious interaction and avoid the use of epinephrine in patients taking clozapine.
- | Journal: Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage. (Pubmed Central) - Oct 31, 2021
Conclusions The present study provides evidence that the LXR agonist AZ876 prevents subendocardial damage, improves global longitudinal strain and E/e' in a mouse model of isoproterenol-induced cardiac damage, accompanied by an upregulation of cardiac polyunsaturated fatty acids levels. Cardiac LXR activation and beneficial endogenous cardiac lipid reprogramming may provide a new therapeutic strategy in cardiac disease with diastolic dysfunction.
- || fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
Clinical, P4 data, Journal, Head-to-Head: A new formulation of fluticasone propionate/salmeterol in a metered-dose inhaler (MDI HFA) allows for the reduction of a daily dose of corticosteroid and provides optimal asthma control - A randomized, multi-center, non-inferiority, phase IV clinical study. (Pubmed Central) - Oct 30, 2021
Cardiac LXR activation and beneficial endogenous cardiac lipid reprogramming may provide a new therapeutic strategy in cardiac disease with diastolic dysfunction. Fluticasone propionate/salmeterol (250 μg/50 μg, twice daily) MDI HFA provides optimal asthma control and is non-inferior to fluticasone propionate/salmeterol (500 μg/50 μg, twice daily) DPI.
- ||| Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Clinical, P1/2 data, P3 data, PK/PD data, Journal: Population Pharmacokinetic Modeling of Fluticasone Furoate, Umeclidinium Bromide, and Vilanterol in Patients with Asthma, Using Data from a Phase IIIA Study (CAPTAIN). (Pubmed Central) - Oct 30, 2021
P3
There was no difference in FF or VI systemic exposure in patients with asthma when administered as either triple (FF/UMEC/VI) or dual therapy (FF/VI). Together with efficacy findings from the CAPTAIN study, our data support the use of single-inhaler FF/UMEC/VI triple therapy for patients with uncontrolled asthma currently receiving ICS/LABA.
- | Journal: Cardiac response to adrenergic stress differs by sex and across the lifespan. (Pubmed Central) - Oct 30, 2021
We suggest that the response to adrenergic stress significantly differs across the lifespan and by sex. Mechanistic definition of these age-related pathways by sex is critical for future research aimed at treating age-related cardiac adrenergic desensitization.
- | Retrospective data, Journal: Uncontrolled asthma: a retrospective cohort study in Japanese patients newly prescribed with medium-/high-dose ICS/LABA. (Pubmed Central) - Oct 30, 2021
In both cohorts, healthcare resource utilization was higher in patients with uncontrolled asthma. Over 20% patients with persistent asthma who initiated medium- or high-dose ICS/LABA were uncontrolled, highlighting unmet need for novel therapies in these patients.
- | Journal: Estradiol-induced inhibition of endoplasmic reticulum stress normalizes splenic CD4 + T lymphocytes following hemorrhagic shock. (Pubmed Central) - Oct 30, 2021
Likewise, ERS inducer tunicamycin induced an adverse effect similarly to that of hemorrhagic shock in sham rats, and aggravated shock-induced effects, also abolished the beneficial effects of E2 and PPT, respectively. Together, the data suggest that E2 produces salutary effects on CD4 T lymphocytes function, and these effects are mediated by ER-α and GPR30, but not ER-β, and associated with the attenuation of hemorrhagic shock-induced ERS.
- || Clinical, Journal: Pragmatic randomized controlled trial for stepping down of asthma controller treatment in patients controlled with low dose inhaled corticosteroid and long-acting beta2 agonist: SIGMA study. (Pubmed Central) - Oct 30, 2021
Both step-down methods were not non-inferior to maintenance of treatment. Step-down therapy can be attempted when patients are stable, but appropriate monitoring and supervision are necessary with precautions for loss of disease control.
- || Clinical, Journal: Spirometric changes in bronchodilation tests as predictors of asthma diagnosis and treatment response in patients with FEV ≥ 80% predicted. (Pubmed Central) - Oct 29, 2021
ΔFEV% in BDT together with FeNO predicted a positive RAT and an asthma diagnosis in patients with a normal FEV and negative BDT. Evidence of pathological changes increases the credibility of the predictive model.
- | Ultibro (glycopyrronium/indacaterol) / Novartis
Journal: Effects of (a Combination of) the Beta-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction. (Pubmed Central) - Oct 28, 2021
In conclusion, glycopyrrolate similarly protects large and small airways, whereas the protective effect of indacaterol in the small, but not the large, airways depends on the contractile stimulus used. Moreover, findings in a guinea pig model indicate that the synergistic bronchoprotective effect of indacaterol and glycopyrrolate is enhanced in COPD.
- || Clinical, Retrospective data, Journal: Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. (Pubmed Central) - Oct 28, 2021
Stratification of this large primary care population according to GOLD criteria predicted the risk of COPD exacerbations. Understanding populations of patients with COPD may enable the optimization of patient care.
- || Review, Journal: Evolving role for pharmacotherapy in NAFLD/NASH. (Pubmed Central) - Oct 27, 2021
Outcomes of promising phase 2 trials in adults with NASH are also available and those have investigated agents including the FGF19 analogue NGM282, the GLP1 agonist liraglutide, the FGF21 analogue Pegbelfermin, the SGLT2 inhibitor Empagliflozin, the ketohexokinase inhibitor PF-06835919, the acetyl-coenzyme A carboxylase inhibitor GS-0976 and the chemokine receptor antagonist Cenicriviroc. Completed and ongoing clinical trials emphasize the need for a more nuanced understanding of the phenotypes of subgroups within NAFLD that may respond to an individualized approach to pharmacotherapy.
- | Preclinical, Journal: Beta-adrenergic receptor antagonism is proinflammatory and exacerbates neuroinflammation in a mouse model of Alzheimer's Disease. (Pubmed Central) - Oct 27, 2021
Additionally, beta-blockers impaired learning and memory and modulated synaptic phagocytosis with implications for synaptic degeneration. These findings warrant further consideration of the proinflammatory consequences of chronic beta-blocker administration, which are not restricted to the periphery in patients with neurodegenerative disorders.
- | Duaklir (aclidinium bromide/formoterol fumarate) / AstraZeneca
Journal: Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. (Pubmed Central) - Oct 27, 2021
Furthermore, evidence supports an improvement in lung function over a 24-hour period with aclidinium/formoterol treatment versus monotherapy and placebo, which may offer an advantage over some once-daily LAMA/LABA combinations. In summary, the recent evidence discussed in this review adds weight to the use of LAMA/LABA combinations as an initial therapy for certain patients newly diagnosed with COPD.
- paclitaxel / Generic mfg.
The lncRNA XIST mediates sensitivity to ERβ targeted therapies in triple negative breast cancer (Hall 1) - Oct 26, 2021 - Abstract #SABCS2021SABCS_1098;
P2
Using multiple in vitro models, we provide evidence that XIST expression is sufficient to induce resistance to ERβ targeted therapies in TNBC and may therefore represent a relevant biomarker for patient stratification. Further strategies to suppress XIST expression may elicit anti-cancer effects on their own and may resensitize a sub-set of ERβ resistant tumors to ERβ agonists.
- | Preclinical, Journal: Incense smoke-induced oxidative stress disrupts tight junctions and bronchial epithelial barrier integrity and induces airway hyperresponsiveness in mouse lungs. (Pubmed Central) - Oct 22, 2021
IS exposure can be problematic for respiratory health, as evidenced by AHR, increased recruitment of inflammatory macrophages and disruption of TJ proteins in the lung, and damage to epithelial barrier function. However, antioxidants may be useful for the treatment of IS-induced airway dysfunction.
- [VIRTUAL] PRECLINICAL PHARMACOKINETIC PROFILING OF ALG- 055009, A POTENT AND SELECTIVE THYROID HORMONE RECEPTOR BETA AGONIST FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS, AND PREDICTION OF ITS HUMAN PHARMACOKINETICS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2154;
ALG-055009 is a potent and selective THR-β agonist with a promising PK profile in rodents and non- rodents; it is projected to result in sub- to low milligram once- daily oral efficacious doses for the treatment of NASH with low risk of drug-drug interactions . Progression of the compound into clinical studies is therefore warranted .
- resmetirom (MGL-3196) / Madrigal Pharma
[VIRTUAL] LIVER VOLUME REDUCTION IN RESMETIROM TREATED NON- CIRRHOTIC AND CIRRHOTIC NASH PATIENTS () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2144;
P2, P3
Reduction in liver volume in resmetirom treated patients may be explained in part by reduction in liver triglycerides (measured by PDFF), but is also likely driven by other changes related to its mechanism of action . LV reduction may be associated with histopathologic improvement of NASH that may be further assessed by data from resmetirom’s Phase 3 MAESTRO-NASH study .
- resmetirom (MGL-3196) / Madrigal Pharma
[VIRTUAL] DEVELOPMENT OF A NOVEL SEVEN-DAY DOSING MOUSE EFFICACY MODEL TO EVALUATE THYROID HORMONE RECEPTOR AGONISTS FOR THE TREATMENT OF NASH () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2129;
LV reduction may be associated with histopathologic improvement of NASH that may be further assessed by data from resmetirom’s Phase 3 MAESTRO-NASH study . This newly developed HCD mouse model provides a rapid and clinically relevant alternative to standard efficacy models for the efficient in vivo screening of THR-β agonists as potential NASH therapeutic agents .
- ASC41 / Ascletis
[VIRTUAL] A PHASE IB STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ASC41, A THR-Β AGONIST, FOR 28-DAYS IN OVERWEIGHT AND OBESE SUBJECTS WITH ELEVATED LDL-C, A POPULATION CHARACTERISTIC OF NAFLD () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2074;
P1
These data support advancement of the ASC41 clinical program for the indication of NASH . The successful development of commercially-ready oral tablet formulation will accelerate ASC41 clinical development .
- ASC41 / Ascletis, ASC42 / Ascletis
[VIRTUAL] ASC43F TABLET AS A ONE-PILL, ONCE-A-DAY FIXED-DOSE COMBINATION (FDC) OF ASC41, A THR-Β AGONIST, AND ASC42, AN FXR AGONIST, DEMONSTRATED COMPARABLE DISSOLUTION PROFILES AND IN VIVO PHARMACOKINETICS VS. SINGLE ASC41 AND ASC42 TABLET () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1986;
The successful development of commercially-ready oral tablet formulation will accelerate ASC41 clinical development . ASC43F is a One-Pill, Once-a-Day FDC of THR-β agonist and FXR agonist for NASH treatment and will improve patient compliance .
- || Review, Journal: Relationship between beta-adrenergic agonists, calpain system activity and beef texture: A systematic review. (Pubmed Central) - Oct 20, 2021
Nine studies evaluated the influence of beta-adrenergic agonists supplementation on meat texture and all found an increase in shear force values. There is strong evidence that beta-adrenergic agonists may increase calpastatin activity in the muscle, causing damage to meat tenderness.
- || Clinical, Journal: Prevalence and Severity of Adolescent Asthma in Yazd, Iran: Based on the 2020 Global Asthma Network (GAN) Survey. (Pubmed Central) - Oct 20, 2021
About 1.2% and 0.8% of participants were using inhaled corticosteroids (ICS) and the combination of ICS and LABA, respectively, which was significantly higher in male participants (p<0.001). According to our findings and in comparison to the previous ISAAC study in Yazd, the prevalence of severe asthma has decreased which indicates better management of asthma during the past two decades.
- || Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Clinical, Journal: Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. (Pubmed Central) - Oct 20, 2021
P3
Safety profiles were consistent with the overall ITT population, with no new safety concerns. FF/UMEC/VI is an effective option with a favorable risk-benefit profile in Japanese patients with uncontrolled moderate or severe asthma on ICS/LABA.
- Miostat (carbachol) / Novartis
[VIRTUAL] Synergistic mucociliary clearance in pig airways by beta-adrenergic and cholinergic agonists () - Oct 19, 2021 - Abstract #NACFCI2021NACFC_I_872;
We discovered that MCCV could be synergistically increased by combining forskolin and low-dose carbachol in ferrets [1], as well as in pigs and, most importantly, in CF ferret tracheas [2]... These findings with agonists approved for human use are consistent with our previous positive studies using forskolin and support continued development of this approach to improve MCC in people with CF.
- [VIRTUAL] Synuclein Alpha Accumulation Drives Lysosomal Dysfunction in Fabry Podocytopathy () - Oct 17, 2021 - Abstract #KIDNEYWEEK2021KIDNEY_WEEK_2368;
Conclusion This study provides strong evidence of a central role of SNCA in lysosomal dysfunction in Fabry disease independent of Gb3 accumulation. The results offer new options for pharmacological strategies to target Fabry podocytopathy.
- | Journal: Novel machine learning can predict acute asthma exacerbation. (Pubmed Central) - Oct 16, 2021
The results offer new options for pharmacological strategies to target Fabry podocytopathy. Models built with ML algorithm from real-world outpatient EHR data accurately predict asthma exacerbation and can be incorporated into clinical decision tools to enhance outpatient care and prevent adverse outcomes.
- | Journal: Effects and mechanism of estrogen receptor β agonist on the migration and oxidative stress of human umbilical vein endothelial cell under high glucose condition (Pubmed Central) - Oct 15, 2021
The protein expression level of VEGF of cells in high glucose+DPN group was significantly lower than the level of normal control group (t=7.206, P<0.05), while the protein expression level of SOD2 of cells in high glucose+DPN group was significantly higher than the level of normal control group (t=2.890, P<0.05). The activation of ERβ can improve the inhibition of HUVECs migration induced by high glucose and alleviate oxidative stress injury induced by high glucose, which may be achieved by promoting the expression of VEGF and SOD2.
- || Clinical, Journal, HEOR: The cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada. (Pubmed Central) - Oct 14, 2021
The activation of ERβ can improve the inhibition of HUVECs migration induced by high glucose and alleviate oxidative stress injury induced by high glucose, which may be achieved by promoting the expression of VEGF and SOD2. As-needed budesonide-formoterol is a cost-saving option for the treatment of mild asthma from the perspective of the Canadian public payer compared with low-dose maintenance ICS plus as-needed SABA.
- | Retrospective data, Journal: Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post-hoc analyses. (Pubmed Central) - Oct 14, 2021
As-needed budesonide-formoterol is a cost-saving option for the treatment of mild asthma from the perspective of the Canadian public payer compared with low-dose maintenance ICS plus as-needed SABA. These post-hoc analyses indicate that inhaled triple therapy with extrafine BDP/FF/G reduces seasonal peaks in moderate-and-severe exacerbations, and confirm the overall utility of adding LAMA to ICS/LABA in the management of asthma.
- [VIRTUAL] IMPACT OF LAMA/LABA ON REDUCING EXACERBATION IN PATIENTS WITH GOLD A OR B COPD () - Oct 13, 2021 - Abstract #CHEST2021CHEST_2003;
CLINICAL IMPLICATIONS: The majority of COPD patients, i.e., group A and B patients, had a low exacerbation risk; however, a considerable number of exacerbation events still occurred in those patients in real-world clinical practice. Although various inhaler treatments are prescribed to group A and B patients, relative to monotherapy, only dual-bronchodilator therapy with LAMA/LABA decreased the risk of future exacerbation, regardless of symptomatic severity and lung function.
- || Review, Journal: Activation of β adrenergic receptor signaling modulates inflammation: a target limiting the progression of kidney diseases. (Pubmed Central) - Oct 13, 2021
Specifically, we summarized the role of β-AR signaling in regulating kidney function and in mediating the progression of acute and chronic kidney diseases. Given their versatile protective effects, β-agonists can be a promising avenue in the treatment of kidney diseases.
- | Preclinical, Journal: Chronic oral administration of a novel estrogen receptor beta agonist enhances memory and alleviates drug-induced vasodilation in young ovariectomized mice. (Pubmed Central) - Oct 13, 2021
These data suggest that chronic ERβ activation can reduce hot flash-like symptoms and enhance spatial and object recognition memories in ovariectomized mice. Thus, the highly selective ERβ agonist EGX358 may be a promising avenue for reducing menopause-related hot flashes and memory dysfunction.
- || Tudorza (aclidinium bromide) / AstraZeneca, Almirall
Clinical, Retrospective data, Journal: Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial. (Pubmed Central) - Oct 13, 2021
P4
Thus, the highly selective ERβ agonist EGX358 may be a promising avenue for reducing menopause-related hot flashes and memory dysfunction. In patients with moderate-to-severe COPD and CV risk factors, the addition of aclidinium to maintenance therapy with LABA or LABA + ICS provided further benefit.